Welcome to our dedicated page for Selecta Biosciences news (Ticker: SELB), a resource for investors and traders seeking the latest updates and insights on Selecta Biosciences stock.
Selecta Biosciences, Inc. (NASDAQ: SELB) pioneers novel biologic therapies using its proprietary SVP™ technology platform to address severe diseases with unmet medical needs. This page serves as the definitive source for verified updates on clinical developments, research breakthroughs, and strategic collaborations.
Access timely updates on SELB's Phase 2 trials for SEL-212 in severe gout and Phase 1 studies of SEL-403 targeting mesothelioma. Stay informed about advancements in gene therapy candidates for metabolic disorders and progress with the RNA Armory® platform for autoimmune treatments.
Our curated news stream covers essential updates including clinical trial milestones, regulatory filings, partnership announcements, and scientific presentations. Investors and researchers will find structured information on SELB's approach to immune tolerance and its implications for therapeutic efficacy.
Bookmark this resource for objective reporting on Selecta Biosciences' progress in redefining biologic treatments. Check regularly for analysis-neutral updates on pipeline developments directly impacting patient care and biopharmaceutical innovation.
Selecta Biosciences (NASDAQ: SELB) is set to host a conference call on November 3, 2022, at 8:30 a.m. ET, to discuss its financial results for Q3 2022 and provide a business update. This conference call will be accessible through telephones or via the company's website. Selecta specializes in precision immune tolerance therapies utilizing its ImmTOR® platform, aimed at enhancing the efficacy of gene and biologic therapies while addressing autoimmune diseases. The company is based in the Greater Boston area.
Selecta Biosciences, Inc. (NASDAQ: SELB) celebrates board member Timothy Springer, Ph.D., who won the prestigious Albert Lasker Basic Medical Research Award for his discovery of integrin adhesion molecules crucial for immune cell interactions. This recognition highlights the significant scientific advancements in immunology, benefiting Selecta’s ImmTOR platform, which aims to develop tolerogenic therapies for autoimmune diseases and enhance gene therapy effectiveness. The company continues its commitment to innovative therapeutic development.
On September 12, 2022, Selecta Biosciences (NASDAQ: SELB) announced its participation in investor conferences in New York. This includes a panel at Cantor Fitzgerald’s Cell and Genetic Medicines Conference on September 15, 2022, and a fireside chat at Jefferies Cell and Genetic Medicine Summit on September 30, 2022. Selecta is leveraging its ImmTOR® platform to develop therapies for autoimmune diseases and gene therapies, demonstrating its role in enhancing biologic efficacy. The full details of the events and the company's innovative approach can be found on their official website.
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology firm specializing in tolerogenic therapies, announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022. The company will host a pre-recorded fireside chat available on September 12 at 7:00 a.m. ET, alongside one-on-one investor meetings. Selecta focuses on leveraging its ImmTOR® platform to enhance gene therapies and treat autoimmune diseases. An archived webcast will be accessible on the company's website for further insights.
Selecta Biosciences, Inc. reported a successful second quarter of 2022, highlighted by the completion of enrollment in the DISSOLVE II study, triggering a $10 million milestone payment from Sobi. With $143.4 million in cash as of June 30, 2022, the company anticipates a financial runway into mid-2024. Collaboration revenue rose to $39.3 million, driven by the DISSOLVE program. Selecta reported a net income of $8.6 million, or $0.06 per share. The company remains on track for joint data readouts in Q1 2023 and expects to initiate a Phase 1 trial for SEL-302 by Q4 2022.
Selecta Biosciences, Inc. (NASDAQ: SELB) announced participation in two investor conferences in August 2022. The BTIG Biotechnology Conference will take place virtually from August 8-9, focusing on one-on-one meetings. The Canaccord Genuity 42nd Annual Growth Conference is scheduled for August 10 in Boston, featuring a fireside chat at 2:30 p.m. ET. Selecta utilizes its ImmTOR® platform to develop therapies for autoimmune diseases and enhance gene therapies. More details can be found on their website.
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology firm focusing on tolerogenic therapies, announced a conference call scheduled for August 4, 2022, at 8:30 a.m. ET to discuss its financial results for Q2 2022 and provide a business update. The call will be accessible via phone, with a replay available for one week. Selecta aims to leverage its ImmTOR® platform to enhance gene therapies and treat autoimmune diseases, positioning itself as a clinical-stage innovator in the space.
Selecta Biosciences (NASDAQ: SELB), a biotechnology company, announced its participation in the Guggenheim I&I Spotlight Series – Treg-based Therapies Conference on July 12-13, 2022. The event will include a fireside chat and one-on-one investor meetings on July 13 at 1:00 p.m. ET. This conference highlights Selecta's ImmTOR platform for developing tolerogenic therapies aimed at autoimmune diseases and enhancing gene therapies. Investors can access the archived webcast via the company's website.
Selecta Biosciences, Inc. (NASDAQ: SELB) has announced an extension of the Research License and Option Agreement with Sarepta Therapeutics for the ImmTOR® platform, with a $2 million payment for the nine-month extension. The agreement covers Duchenne Muscular Dystrophy (DMD) and Limb-Girdle Muscular Dystrophies (LGMD). Additionally, the DISSOLVE II Phase 3 study for SEL-212, targeting chronic refractory gout, is on track for full enrollment by Q2 2022, potentially triggering a $10 million milestone payment from Sobi. Topline data from DISSOLVE studies is expected in Q1 2023.
